PMID- 16249844
OWN - NLM
STAT- MEDLINE
DCOM- 20060214
LR  - 20181113
IS  - 0941-1291 (Print)
IS  - 0941-1291 (Linking)
VI  - 35
IP  - 11
DP  - 2005
TI  - Peritoneal carcinoembryonic antigen level for predicting locoregional and distant 
      spread of gastric cancer.
PG  - 919-24
AB  - PURPOSE: Peritoneal recurrence is not an uncommon cause of death after surgery 
      for gastric cancer, even after surgery with curative intent. This indicates that 
      there is undetected residual disease in the peritoneal cavity. We conducted this 
      study to determine the value of peritoneal and serum carcinoembryonic antigen 
      (CEA) levels and peritoneal washing cytology in predicting the locoregional and 
      distant spread of gastric cancer. METHODS: We prospectively evaluated 70 
      consecutive patients with gastric cancer by measuring peritoneal CEA (pCEA) and 
      serum CEA (sCEA) levels and peritoneal washing cytology results, and studying 
      their effect on the histopathologic properties. The effect of the pCEA level on 
      disease-free survival (DFS) and overall survival (OS) was also evaluated in 
      patients treated with curative intent. RESULTS: Twenty-one (30%) patients had 
      sCEA levels >10 ng/ml, whereas 25 patients (35.7%) had pCEA levels >10 ng/g 
      protein and 26 patients (37.1%) had positive cytology. The pCEA levels were 
      significantly higher in patients with hepatic metastases (P = 0.034), or serosal 
      (P = 0.028), and peritoneal (P = 0.026) involvement, whereas the sCEA levels were 
      significantly higher only in patients with hepatic metastases (P = 0.04). 
      Similarly, positive cytology was mainly detected in patients with hepatic 
      metastases (P = 0.004). The pCEA levels significantly affected DFS (P = 0.002) 
      and OS (P = 0.01) in 34 patients treated with curative intent. CONCLUSION: Since 
      pCEA levels are more useful for predicting locoregional recurrence, their 
      measurement during surgery may help plan the most appropriate surgical strategy 
      and adjuvant therapy.
FAU - Cetin, Bahadir
AU  - Cetin B
AD  - Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey.
FAU - Atalay, Can
AU  - Atalay C
FAU - Aslan, Sabahattin
AU  - Aslan S
FAU - Babacan, Bahattin
AU  - Babacan B
FAU - Hatipoglu, Celal
AU  - Hatipoglu C
FAU - Akinci, Melih
AU  - Akinci M
FAU - Cetin, Abdullah
AU  - Cetin A
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (Carcinoembryonic Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoembryonic Antigen/*analysis
MH  - Cytodiagnosis
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*diagnosis/*secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local/*diagnosis
MH  - *Peritoneal Lavage
MH  - Peritoneal Neoplasms/*diagnosis/*secondary
MH  - Predictive Value of Tests
MH  - Sensitivity and Specificity
MH  - Stomach Neoplasms/mortality/pathology/*surgery
MH  - Survival Rate
EDAT- 2005/10/27 09:00
MHDA- 2006/02/16 09:00
CRDT- 2005/10/27 09:00
PHST- 2004/03/04 00:00 [received]
PHST- 2005/01/18 00:00 [accepted]
PHST- 2005/10/27 09:00 [pubmed]
PHST- 2006/02/16 09:00 [medline]
PHST- 2005/10/27 09:00 [entrez]
AID - 10.1007/s00595-005-3057-9 [doi]
PST - ppublish
SO  - Surg Today. 2005;35(11):919-24. doi: 10.1007/s00595-005-3057-9.